Trimetinib (Xalkori) is the main anticancer drug developed by a New Zealand pharmaceutical company. It is used in patients with metastatic prostate cancer and to treat metastatic lung cancer and leukemia.
Trimetinib is known as a PI3K/Akt inhibitor because of its ability to prevent the activity of this protein from increasing in the cell. This means that there will be less formation of receptors that can bind the proteins that allow the cell to grow and multiply. It also prevents the growth of new cancer cells.
Trimetinib is an intravenous drug and has a short half-life of just a few hours. It is given to patients in a three-times-a-day dosing schedule.
Trimetinib has few reported side effects. It should not be taken by women who are breast-feeding or are pregnant. It is available only in combination with other drugs such as azathioprine and rotenone.
In some cases, it may help to slow down the symptoms of ulcerative colitis. There are also reports of a reduction in the incidence of stomach ulcers with the use of trametinib.
Trimetinib has been shown to cause very low levels of flu-like symptoms in some patients. It has been reported that it causes "flu-like" symptoms in some patients. Some people have had symptoms such as fever, vomiting, muscle aches, sore throat, diarrhea, and blurred vision, but these symptoms have not been reported by people who were taking trametinib.
Themost common side effects that have been reported with the use of trametinib are headache, fatigue, skin rashes, gastrointestinal upset, and diarrhea. These side effects may go away over time, but others will continue to occur for a few months after treatment.
Men are reported to experience more nausea, vomiting, diarrhea, and headaches than women. For this reason, they are usually given two tablets of trametinib with a decongestant. Women need to be given three tablets, but the treatment schedule may vary.
Renal problems, urinary tract infections, and bone pain are also reported. A patient who takes trametinib and has an infection in the urinary tract should be seen by a doctor immediately. In addition, patients who take trametinib and have a urinary tract infection should be checked at least twice a week.
Even though there is no evidence of permanent kidney damage, trametinib can still cause a kidney failure. In addition, it has been reported that trametinib is associated with a change in the flow of blood in the urinary tract, making it harder for the urine to be filtered by the kidneys. If this occurs, the result is more frequent urination, which in turn leads to more serious kidney damage.
These side effects are temporary and usually disappear over time. Trimetinib should be used only by people who are very sure that they will not get them again. Taking the drug while you have other medications that can trigger side effects is extremely dangerous.